Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 7/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 3/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8719273 | 0.79 | DPP4 (0.63) | POLA1XDHDPP4ADORA3 | |
| Tetrabuthylammonium SCHEMBL200612 | 0.72 | CDK2 (0.68) | DPP4CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL7293081 | 0.70 | DPP4 (0.56) | POLA1XDHDPP4CDK1CCNB1 | |
| SCHEMBL16146631 | 0.68 | XDH (0.65) | XDHCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4451634 | 0.68 | XDH (0.61) | XDHDPP4ADORA3 | |
| SCHEMBL7110774 | 0.67 | XDH (0.51) | XDHDPP4CDK1CCNB1CCNA2 | |
| Purine SCHEMBL10869621 | 0.67 | KDM4E (0.50) | POLA1XDHDPP4 | |
| Hydrochloric Acid SCHEMBL7736838 | 0.66 | DPP4 (0.59) | POLA1XDHDPP4CDK2ADORA3 | |
| SCHEMBL24500763 | 0.64 | XDH (0.56) | XDHDPP4CDK2ADORA3 | |
| SCHEMBL2997392 | 0.64 | DPP4 (0.61) | POLA1XDHDPP4CDK2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101848891-A | Preparation of synthetic nucleosides by pi-allyl transition metal complex formation | UNIV EMORY | 2010-09-29 | — | — | CN | disclosed |
| US-20100204463-A1 | Preparation Of Synthetic Nucleosides via Pi-Allyl Transition Metal Complex Formation | EMORY UNIVERSITY | 2010-08-12 | — | — | US | disclosed |
| EP-2185508-A1 | PREPARATION OF SYNTHETIC NUCLEOSIDES VIA pi-ALLYL TRANSITION METAL COMPLEX FORMATION | Emory University (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009021114-A1 | PREPARATION OF SYNTHETIC NUCLEOSIDES VIA π-ALLYL TRANSITION METAL COMPLEX FORMATION | EMORY UNIVERSITY (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204463-A1 | Preparation Of Synthetic Nucleosides via Pi-Allyl Transition Metal Complex Formation | PAICS, POLRMT, ZC3HAV1 | POLA1 22/4885XDH 1752/4885DPP4 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.